RUA Life Sciences (LSE:RUA) reported continued strong activity within its UK contract development and manufacturing (CDMO) division, where two core manufacturing contracts are currently supporting revenues. The business is also building a development pipeline valued at roughly £500,000 expected to be billed during the current financial year. Around 60% of these projects relate to products that are already approved or approaching regulatory approval, providing visibility toward potential manufacturing contracts worth more than £5m annually and reinforcing management’s view that the company is approaching a key growth inflection.
Performance at the group’s Abiss subsidiary is currently below budget as a major customer reduces existing inventory levels. RUA is negotiating arrangements aimed at aligning stock positions while securing revenue visibility for the next two years. Elsewhere, the biomaterials division is performing broadly in line with previous periods, with further growth expected from a new Elast-Eon supply agreement and the possibility of higher royalty income. In the structural heart segment, the company has signed Heads of Terms for third-party funding to support pre-clinical development of a novel heart valve based on its AurTex technology, highlighting the strategic value of its intellectual property and partnerships.
The company’s outlook is supported by steady revenue growth and a relatively conservative balance sheet. However, profitability remains limited and operating cash flow is still negative. Technical indicators remain constructive, reflecting an established upward trend in the share price, although the company’s very high P/E ratio weighs on its overall valuation profile.
More about RUA Life Sciences
RUA Life Sciences is an AIM-listed UK medical device group specialising in implantable medical textiles and its proprietary biostable polymer Elast-Eon. The company provides contract development and manufacturing services while also licensing biomaterial technologies to medical device partners. The group owns Abiss in France, which manufactures implantable medical devices, and is advancing structural heart technologies including heart valve applications based on its AurTex platform.
Leave a Reply